• Something wrong with this record ?

Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus

O. Terrier, S. Dilly, A. Pizzorno, D. Chalupska, J. Humpolickova, E. Bouřa, F. Berenbaum, S. Quideau, B. Lina, B. Fève, F. Adnet, M. Sabbah, M. Rosa-Calatrava, V. Maréchal, J. Henri, A. Slama-Schwok

. 2021 ; 26 (9) : . [pub] 20210429

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21018763

Grant support
CoVNucleovir Sorbonne University and Sorbonne Foundation
APHP200387 AP-HP
FR 20/02351 INSERM Reacting and Merieux Foundation

There is an urgent need for specific antiviral treatments directed against SARS-CoV-2 to prevent the most severe forms of COVID-19. By drug repurposing, affordable therapeutics could be supplied worldwide in the present pandemic context. Targeting the nucleoprotein N of the SARS-CoV-2 coronavirus could be a strategy to impede viral replication and possibly other essential functions associated with viral N. The antiviral properties of naproxen, a non-steroidal anti-inflammatory drug (NSAID) that was previously demonstrated to be active against Influenza A virus, were evaluated against SARS-CoV-2. Intrinsic fluorescence spectroscopy, fluorescence anisotropy, and dynamic light scattering assays demonstrated naproxen binding to the nucleoprotein of SARS-Cov-2 as predicted by molecular modeling. Naproxen impeded recombinant N oligomerization and inhibited viral replication in infected cells. In VeroE6 cells and reconstituted human primary respiratory epithelium models of SARS-CoV-2 infection, naproxen specifically inhibited viral replication and protected the bronchial epithelia against SARS-CoV-2-induced damage. No inhibition of viral replication was observed with paracetamol or the COX-2 inhibitor celecoxib. Thus, among the NSAID tested, only naproxen combined antiviral and anti-inflammatory properties. Naproxen addition to the standard of care could be beneficial in a clinical setting, as tested in an ongoing clinical study.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018763
003      
CZ-PrNML
005      
20210830100332.0
007      
ta
008      
210728s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/molecules26092593 $2 doi
035    __
$a (PubMed)33946802
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Terrier, Olivier $u CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France
245    10
$a Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus / $c O. Terrier, S. Dilly, A. Pizzorno, D. Chalupska, J. Humpolickova, E. Bouřa, F. Berenbaum, S. Quideau, B. Lina, B. Fève, F. Adnet, M. Sabbah, M. Rosa-Calatrava, V. Maréchal, J. Henri, A. Slama-Schwok
520    9_
$a There is an urgent need for specific antiviral treatments directed against SARS-CoV-2 to prevent the most severe forms of COVID-19. By drug repurposing, affordable therapeutics could be supplied worldwide in the present pandemic context. Targeting the nucleoprotein N of the SARS-CoV-2 coronavirus could be a strategy to impede viral replication and possibly other essential functions associated with viral N. The antiviral properties of naproxen, a non-steroidal anti-inflammatory drug (NSAID) that was previously demonstrated to be active against Influenza A virus, were evaluated against SARS-CoV-2. Intrinsic fluorescence spectroscopy, fluorescence anisotropy, and dynamic light scattering assays demonstrated naproxen binding to the nucleoprotein of SARS-Cov-2 as predicted by molecular modeling. Naproxen impeded recombinant N oligomerization and inhibited viral replication in infected cells. In VeroE6 cells and reconstituted human primary respiratory epithelium models of SARS-CoV-2 infection, naproxen specifically inhibited viral replication and protected the bronchial epithelia against SARS-CoV-2-induced damage. No inhibition of viral replication was observed with paracetamol or the COX-2 inhibitor celecoxib. Thus, among the NSAID tested, only naproxen combined antiviral and anti-inflammatory properties. Naproxen addition to the standard of care could be beneficial in a clinical setting, as tested in an ongoing clinical study.
650    _2
$a zvířata $7 D000818
650    _2
$a antiflogistika nesteroidní $x farmakologie $7 D000894
650    _2
$a antivirové látky $x farmakologie $7 D000998
650    _2
$a COVID-19 $7 D000086382
650    _2
$a buněčné linie $7 D002460
650    _2
$a Cercopithecus aethiops $7 D002522
650    _2
$a přehodnocení terapeutických indikací léčivého přípravku $7 D058492
650    _2
$a lidé $7 D006801
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a naproxen $x farmakologie $7 D009288
650    _2
$a nukleoproteiny $x antagonisté a inhibitory $x metabolismus $7 D009698
650    _2
$a SARS-CoV-2 $x účinky léků $x fyziologie $7 D000086402
650    _2
$a Vero buňky $7 D014709
650    _2
$a virové proteiny $x antagonisté a inhibitory $x metabolismus $7 D014764
650    _2
$a replikace viru $x účinky léků $7 D014779
650    _2
$a farmakoterapie COVID-19 $7 D000093485
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dilly, Sébastien $u Cancer Biology and Therapeutics Team, INSERM, UMR_S 938, Centre de Recherche Saint-Antoine, Sorbonne Universitè, F-75012 Paris, France
700    1_
$a Pizzorno, Andrés $u CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France
700    1_
$a Chalupska, Dominika $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 11720 Prague, Czech Republic
700    1_
$a Humpolickova, Jana $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 11720 Prague, Czech Republic
700    1_
$a Bouřa, Evžen $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 11720 Prague, Czech Republic
700    1_
$a Berenbaum, Francis $u INSERM, UMR_S 938, Centre de Recherche Saint-Antoine, Sorbonne University, and Department of Rheumatology, AP-HP Saint-Antoine Hospital, F-75012 Paris, France
700    1_
$a Quideau, Stéphane $u ISM, UMR-CNRS 5255, Université de Bordeaux, F-33405 Talence, France $u Institut Universitaire de France, F-75231 Paris, France
700    1_
$a Lina, Bruno $u CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France
700    1_
$a Fève, Bruno $u Genetic and acquired lipodystrophies Team, INSERM, UMR_S 938, Centre de Recherche Saint-Antoine, Sorbonne Université, F-75012 Paris, France $u Department of Endocrinology, AP-HP Saint-Antoine Hospital, Institut Hospitalo-Universitaire de Cardio-métabolisme et Nutrition (ICAN), CRMR PRISIS, F-75012 Paris, France
700    1_
$a Adnet, Frédéric $u Service d'Urgences-SAMU-SMUR, Hôpital Avicenne, AP-HP, F-93000 Bobigny, France
700    1_
$a Sabbah, Michèle $u Cancer Biology and Therapeutics Team, INSERM, UMR_S 938, Centre de Recherche Saint-Antoine, Sorbonne Universitè, F-75012 Paris, France
700    1_
$a Rosa-Calatrava, Manuel $u CIRI, Centre International de Recherche en Infectiologie, (Team VirPath), Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France
700    1_
$a Maréchal, Vincent $u Cancer Biology and Therapeutics Team, INSERM, UMR_S 938, Centre de Recherche Saint-Antoine, Sorbonne Universitè, F-75012 Paris, France
700    1_
$a Henri, Julien $u Laboratoire de Biologie Computationnelle et Quantitative, Institut de Biologie Paris-Seine, UMR-CNRS 7238, Sorbonne Université, F-75005 Paris, France
700    1_
$a Slama-Schwok, Anny $u Cancer Biology and Therapeutics Team, INSERM, UMR_S 938, Centre de Recherche Saint-Antoine, Sorbonne Universitè, F-75012 Paris, France
773    0_
$w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 26, č. 9 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33946802 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100332 $b ABA008
999    __
$a ok $b bmc $g 1689757 $s 1139209
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 26 $c 9 $e 20210429 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
GRA    __
$a CoVNucleovir $p Sorbonne University and Sorbonne Foundation
GRA    __
$a APHP200387 $p AP-HP
GRA    __
$a FR 20/02351 $p INSERM Reacting and Merieux Foundation
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options